Study of Rituximab to Treat Chronic Renal Transplant Rejection

NCT ID: NCT00476164

Last Updated: 2020-03-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 62 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-01-31
• Study Completion Date: 2017-04-30

Brief Summary

Purpose of clinical trial; Evaluate the effectiveness of rituximab in C4d+ CAN

Primary objective; To determine whether anti-CD20 therapy can stabilize or improve renal function and/or proteinuria in patients with C4d+, chronic (humoral) rejection in whom standard therapeutic approaches have failed.

Secondary objective (s);

• To compare patient and graft survival between control and rituximab-treated groups
• To evaluate the adverse effect profile of rituximab in this group
• To correlate changes in circulating B cell numbers, anti-HLA and non-HLA Ab profiles and titre with responses to standard therapy and / or rituximab
• To correlate changes in T cell responsiveness to alloantigens with responses to standard therapy and / or rituximab

Study Design; Prospective, randomised, two arm, open-labeled

Study Endpoints; Primary

• Rate of deterioration in renal function, defined by slope of reciprocal creatinine plot, on samples taken 3-5 months post-randomisation.
• Change in degree of proteinuria, where present, at 3-5 months post-randomisation 2˚ endpoints, determined at 3-5 months post-randomisation and at 1, 2 and 3 years post-recruitment are;
• Rate of deterioration in renal function, defined by slope of reciprocal creatinine plot, determined by analysis of samples taken since previous assessment.
• Patient survival
• Graft survival
• Incidence of culture positive infection
• Incidence of malignancy
• Degree of proteinuria
• Changes in circulating CD20+ cells in peripheral blood
• Changes in anti-graft Ab titres, (measured every 3 months)
• Changes in T cell responsiveness to alloantigens (measured every 3 months).

Sample Size; 15 patients to be randomised to each arm (i.e. 30 patients randomised). Up to 120 patients will need to be enrolled into the study. In addition, in those participants that received a living donor kidney, these donors will be approached to provide up to 5 samples of blood to help with the in vitro analyses.

Summary of eligibility criteria;

• Male or female renal allograft recipients 18-70 years of age
• more than 6/12 post-transplantation
• Either deteriorating allograft function on reciprocal creatinine plot or significant proteinuria or both.
• C4d+/- CAN on renal allograft biopsy

Investigational medicinal product and dosage; Rituximab, 1g on day 0 and 1g on day 14

Active comparator product(s); None

Route(s) of administration; Intravenous infusion

Maximum duration of treatment of a subject; 14 days with rituximab. The treatment arms of the study, including optimisation period, formal run-in and post-randomisation phase lasts for 10 months post-recruitment.

Procedures; Screening & enrollment. Potentially eligible patients will be identified by screening renal allograft biopsies performed for 'creeping creatinine' and/or proteinuria. Recruitment by informed consent prior to enrollment.

Procedures; Baseline. In addition to routine tests, blood for anti-HLA and non-HLA antibody analysis and for peripheral blood mononuclear cell (PBMC) purification.

Procedures; Treatment period. 3 month run-in period on optimal conventional immunosuppressive therapy, preceded by up to 2 months to allow tailored-optimization. Patients will be reviewed at least six times in their normal transplant clinic appointments for routine blood biochemistry, full blood count and urine analysis. At the end of the run-in period, further blood will be taken for anti-graft antibody analysis and PBMC purification. Those patients in whom allograft function stabilises and/or proteinuria improves will have normal transplant clinic follow-up appointments and have blood taken for further anti-graft antibody and PBMC purification up to every 3 months for 3 years. Those with continued deterioration in either allograft function or persisting or worsening proteinuria will be randomised. These patients will be reviewed during their normal transplant clinic appointments until the primary end-point and will need to have at least 6 routine blood biochemistry, full blood count and urine analysis during the final 3 months of this period, post-randomisation. At the primary end-point, further blood will be taken for anti-graft antibody analysis and PBMC.

Procedures; End of Study. •Follow up will continue for 3 years, with blood taken for anti-graft antibody analysis and PBMC purification every three months

Procedures for safety monitoring during trial; Regular patient interviews and examination, routine haematological and biochemical analyses. Serious adverse events will be reported and forwarded to the sponsor, MHRA, LREC and Roche as appropriate The WLRATC transplant research committee will discuss the trial and any safety concerns at their regular three monthly meetings. Data will be reviewed after 30 and also after 60 people have been enrolled.

Criteria for withdrawal of patients on safety grounds; Serious adverse effects related to rituximab infusion

Conditions

Kidney Transplantation; Graft Rejection; Immunosuppression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Rituximab

Infusion of 2 x 1g of rituximab, 14 days apart

Group Type: EXPERIMENTAL

Rituximab

Intervention Type: DRUG

2 doses of 1g 14 days apart

2

Group Type: SHAM_COMPARATOR

Control arm

Intervention Type: OTHER

Continue of optimised oral immunosuppression

Interventions

Rituximab

2 doses of 1g 14 days apart

Intervention Type: DRUG

Control arm

Continue of optimised oral immunosuppression

Intervention Type: OTHER

Other Intervention Names

Mabthera

Eligibility Criteria

Inclusion Criteria

• Functioning kidney allograft (with estimated (e) GFR by MDRD >20) and be >6/12 post-transplantation
• Deteriorating allograft function as defined by linear regression of reciprocal creatinine plot. Deterioration will be defined as a negative slope over at least the preceding 3 months (with at least 6 creatinines included) with an adjusted r2 >0.35 and a p value of ≤0.05 compared to horizontal baseline. Deterioration will be confirmed by reduction in Cockcroft-Gault (CG) eGFR over the same period (to exclude increases in body mass as a cause of a negative slope on reciprocal creatinine plots) OR significant proteinuria as assessed by a urine protein/creatinine ratio of ≥50
• CAN, by Banff '97 criteria, and/or transplant glomerulopathy on renal allograft biopsy performed within 6/12 of enrolment
• Diffuse, linear C4d deposition on at least 25% of peritubular capillary (PTC) and/or glomerular EC of renal transplant biopsy when assessed by immunoperoxidase or >50% of PTC (alone) when assessed by immunofluorescence OR PTCitis OR glomerulitis with combined PTC/g score of ≥2.

Exclusion Criteria

• Ages below 18 years of age
• Suspicion of pregnancy confirmed by positive HCG pregnancy test
• Untreated ureteric obstruction on ultrasound of allograft
• History of acute allograft rejection in preceding 3/12
• History of MI in preceding 3/12
• History of malignancy in previous 5 years (excluding tumours limited to skin)
• Symptomatic IHD
• Recipient of simultaneous pancreas/kidney transplant
• Recipient of ABO-incompatible kidney
• Recipient who underwent an HLA desensitisation procedure prior to transplantation
• Evidence, on examination of renal allograft biopsy specimen, of recurrent or de-novo disease (except IgA deposition in absence of mesangial proliferation)
• Evidence, on examination of renal allograft biopsy specimen, of CNI toxicity IF ACCOMPANIED by mostly supra-therapeutic CNI trough levels in the 6 month period preceding biopsy.
• Documented allergy to mouse or chimeric human/mouse proteins
• HepBsAg+, HepBcAb+, HCV Ab+ or HIV+.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medical Research Council

OTHER_GOV

Sponsor Role: collaborator

Roche Pharma AG

INDUSTRY

Sponsor Role: collaborator

King's College London

OTHER

Sponsor Role: lead

Responsible Party

A. Dorling

Professor of Transplant Inflammation and Repair

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Anthony Dorling, PhD FRCP

Role: PRINCIPAL_INVESTIGATOR

King's College London

Locations

University Hospital Birmingham

Birmingham, , United Kingdom

East Kent Hospitals University NHS Foundation Trust

Canterbury, , United Kingdom

Univeristy Hospital of Wales

Cardiff, , United Kingdom

Epsom & St Helier University Hospitals Trust

Carshalton, , United Kingdom

Western Infirmary

Glasgow, , United Kingdom

Hull Royal Infirmary

Hull, , United Kingdom

St Jame's University Hospital

Leeds, , United Kingdom

The Royal Free Hospital

London, , United Kingdom

King's College London, Guy's Hospital

London, , United Kingdom

Imperial College London and West London Renal & Transplantation Centre

London, , United Kingdom

Manchester Royal Infirmary

Manchester, , United Kingdom

Countries

United Kingdom

References

Shiu KY, Stringer D, McLaughlin L, Shaw O, Brookes P, Burton H, Wilkinson H, Douthwaite H, Tsui TL, Mclean A, Hilton R, Griffin S, Geddes C, Ball S, Baker R, Roufosse C, Horsfield C, Dorling A. Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts. Front Immunol. 2020 Feb 5;11:79. doi: 10.3389/fimmu.2020.00079. eCollection 2020.

Reference Type: RESULT

PMID: 32117242 (View on PubMed)

Related Links

https://kclpure.kcl.ac.uk/portal/en/publications/effect-of-optimised-immunosuppression-including-rituximab-on-antidonor-alloresponses-in-patients-with-chronically-rejecting-renal-allografts(701fe5d0-440a-49fb-9ab2-28dfcccca876).html

Pre-print version of the manuscript describing the trial outcomes

https://www.frontiersin.org/articles/10.3389/fimmu.2020.00079/full

Full print version of trial outcomes manuscript

Other Identifiers

2006-002330-38

Identifier Type: -

Identifier Source: org_study_id